ERBB2 and breast carcinoma: Cross-comparison of TKIs in breast cancer cell lines, given that all three TKIs are approved for clinical use in the treatment of HER2+ breast cancer, the anti-proliferative inhibitory potency of the TKIs on the 12 breast cancer cell lines from the 115-cell line panel was compared.